"Logan University is thrilled to offer its Doctor of Chiropractic students a new scholarship opportunity, with the help from The Joint Corp.," said Clay McDonald, DC, MBA, JD, Logan University president. "We are tremendously grateful for the dedicated support of The Joint Corp. as we partner on this important effort to provide financial resources to deserving students." This annual scholarship is the largest gift The Joint Corp. has made to any nonprofit. The fundamental purpose of an endowed scholarship is ...

公司任命 - 公司任命Krischelle Tennessen为首席人力资源官和Michael Simpson为首席信息官[1] Krischelle Tennessen - Krischelle Tennessen将负责公司文化、人力资源战略和流程以及人才发展[2] Michael Simpson - Michael Simpson将负责组织的所有技术领域[3]

The Joint Corp. (JYNT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Since ...

The Joint Corp. (JYNT) shares soared 10.1% in the last trading session to close at $13.08. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 11.9% gain over the past four weeks. The Joint extended its rally for the second straight day, following the strong fourth-quarter 2023 results released on Mar 7. It reported an adjusted earnings per share of 7 cents, which outpaced the Zacks Consensus Estimate of 3 cents. The top line beat th ...

The Joint Corp. (JYNT) shares have jumped 30% since it reported fourth-quarter 2023 financial results. The strong quarterly results were primarily due to continued organic growth and an increased number of clinics, partially offset by higher expenses. In the quarter under review, it witnessed an adjusted earnings per share of 7 cents, beating the Zacks Consensus Estimate of 3 cents. The bottom line also improved from adjusted earnings of 4 cents per share a year ago. Revenues of The Joint amounted to $30.6 ...

业绩总结 - 2023年第四季度公司营收为30.6亿美元，较2022年增长11%[11] - 2023财年总收入为117.7百万美元，较2022年增长16%[13] - 2023年净亏损为9.8百万美元，较2022年净收入下降[13] 用户数据 - 2023年治疗的独特患者数量为1.7百万人，较2022年的1.6百万人有所增加[4] - 2023年新增患者数量为932千人，较2022年的845千人有所增加[4] 未来展望 - 2024年系统销售额预期为530至545百万美元，较2023年实际销售额增长[14] - 2024年新特许诊所开设预期为60至75家[14] 新产品和新技术研发 - 大部分公司诊所采取转让特许经营策略，以提高价值、集中布局，并通过销售框架实现价值最大化[7] 市场扩张和并购 - 2023年新增的连锁诊所数量为935家，其中55家为特许经营，75家为授权销售[6] - 2023年销售的特许经营许可证数量为283个，处于活跃开发阶段的诊所数量为1248家[8] 负面信息 - 2023年公司运营亏损为0.1亿美元，较2022年净收入下降，主要受到税收费用影响[11]

财务数据和关键指标变化 - 2023年全年系统销售额增长12%至4.88亿美元,2023年第四季度系统销售额增长11%至1.331亿美元 [15][34] - 2023年全年收入增长16%至1.177亿美元,2023年第四季度收入增长11%至3,060万美元 [16][34] - 2023年全年调整后EBITDA增长6%至1,220万美元,2023年第四季度调整后EBITDA为400万美元,与2022年同期持平 [16][41] - 2023年12月31日现金余额为1,820万美元,较2022年12月31日的970万美元增加 [45] 各条业务线数据和关键指标变化 - 2023年全年新增114家门店,其中104家特许经营和10家自营,2022年新增137家门店 [17] - 2023年关闭13家特许经营和4家自营门店,占总门店数不到2% [17] - 2023年12月31日,公司共有935家门店,其中800家特许经营和135家自营,特许经营占比86% [17][18] 各个市场数据和关键指标变化 - 2023年全年13个月以上门店同店销售增长4% [15][43] - 2023年全年48个月以上成熟门店同店销售下降1% [43] - 2023年第四季度13个月以上门店同店销售增长5%,48个月以上成熟门店同店销售下降1% [34] 公司战略和发展方向及行业竞争 - 公司正在执行重新特许经营的战略,计划在未来一年内将大部分自营门店转让给现有特许经营商 [20][21][51] - 公司将重点关注提高新患者转化率、增加新患者数量和降低患者流失率 [26][53][54] - 公司将加强营销力度,调整媒体组合、增加营销投放、开发新的促销活动和提升现有患者参与度 [28][29][30][31][32] - 公司将继续优化医生招聘和留存,提升患者体验,提高门店经营效率和盈利能力 [53][54][55] 管理层对经营环境和未来前景的评论 - 2023年经营环境仍存在不确定性,但公司通过提高营销效率、优化门店组合等措施实现了增长 [11][12] - 2024年公司将继续专注于提高新患者数量、延长患者参与时间和重新吸引流失患者,以提升整体业绩 [53][54][55] - 由于重新特许经营的不确定性,公司未来收入和利润的具体指引难以预测,但预计通过减少自营门店将有助于提高整体盈利能力 [47][48][49][50][51] 问答环节重要的提问和回答 问题1 **George Kelly 提问** 询问重新特许经营的进展和时间表 [59][60] **Peter Holt 回答** 公司正在与现有特许经营商和其他潜在买家洽谈,预计2024年和2025年将完成大部分交易 [61][62][63] 问题2 **Ryan Meyers 提问** 询问成熟门店同店销售下降的原因 [68] **Jake Singleton 回答** 随着市场饱和,需要更多关注新患者获取和现有患者留存,公司正在采取相应的营销措施应对 [69][70] 问题3 **Jeff Van Sinderen 提问** 询问2024年新特许经营店数的预期 [75][76][77] **Peter Holt 回答** 由于重新特许经营的影响,新特许经营店数预计会低于2023年,但具体数字公司暂不指引 [76][77]

The Joint Corp. (JYNT) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 133.33%. A quarter ago, it was expected that this company would post earnings of $0.04 per share when it actually produced a loss of $0.05, delivering a surprise of -225%. Over the last four quarters, the company ...

- Grew 2023 Revenue 16%, System-wide Sales 12%, and System-wide Comp Sales 4% vs. 2022 - - Increased Clinic Count to 935 at Year-end 2023, Initiating Refranchising Program - SCOTTSDALE, Ariz., March 07, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ:JYNT), a national operator, manager, and franchisor of chiropractic clinics, reported its financial results for the quarter and year ended December 31, 2023. Financial Highlights: Q4 2023 Compared to Q4 2022 Grew revenue 11% to $30.6 million. Recorded net loss ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to ________ Commission File Number: 001-36724 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 90-0544160 (State or Other Jurisdiction ...